Effects of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] on Cortical Bone in Postmenopausal Women With Osteoporosis
Open Access
- 1 March 2003
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 18 (3) , 539-543
- https://doi.org/10.1359/jbmr.2003.18.3.539
Abstract
Treatment with teriparatide (rDNA origin) injection {teriparatide, recombinant human parathyroid hormone (1–34) [rhPTH(1–34)]}reduces the risk of vertebral and nonvertebral fragility fractures and increases cancellous bone mineral density in postmenopausal women with osteoporosis, but its effects on cortical bone are less well established. This cross‐sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once‐daily, self‐administered subcutaneous injections of placebo (n = 35) or teriparatide 20 μg (n = 38) or 40 μg (n = 28). We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment. The results were adjusted for age, height, and weight. Compared with placebo, patients treated with teriparatide 40 μg had significantly higher total bone mineral content, total and cortical bone areas, periosteal and endocortical circumferences, and axial and polar cross‐sectional moments of inertia. Total bone mineral content, total and cortical bone areas, periosteal circumference, and polar cross‐sectional moment of inertia were also significantly higher in the patients treated with teriparatide 20 μg compared with placebo. There were no differences in total bone mineral density, cortical thickness, cortical bone mineral density, or cortical bone mineral content among groups. In summary, once‐daily administration of teriparatide induced beneficial changes in the structural architecture of the distal radial diaphysis consistent with increased mechanical strength without adverse effects on total bone mineral density or cortical bone mineral content.Keywords
This publication has 11 references indexed in Scilit:
- The Anabolic Effects of Parathyroid HormoneOsteoporosis International, 2002
- Biomechanics of Bone: Determinants of Skeletal Fragility and Bone QualityOsteoporosis International, 2002
- Bone Quality Parameters of the Distal Radius as Assessed by pQCT in Normal and Fractured WomenOsteoporosis International, 2001
- Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2001
- Intermittently Administered Human Parathyroid Hormone(1–34) Treatment Increases Intracortical Bone Turnover and Porosity Without Reducing Bone Strength in the Humerus of Ovariectomized Cynomolgus MonkeysJournal of Bone and Mineral Research, 2001
- Alendronate Increases Bone Density and Bone Strength at the Distal Radius in Postmenopausal WomenJournal of Bone and Mineral Research, 1999
- Anabolic Effects of Human Biosynthetic Parathyroid Hormone Fragment (1–34), LY333334, on Remodeling and Mechanical Properties of Cortical Bone in RabbitsJournal of Bone and Mineral Research, 1999
- Prediction of fracture load at different skeletal sites by geometric properties of the cortical shellJournal of Bone and Mineral Research, 1996
- Geometric variables from DXA of the radius predict forearm fracture load in vitroCalcified Tissue International, 1993
- The distribution of cortical and trabecular bone mass along the lengths of the radius and ulna and the implications forin vivo bone mass measurementsCalcified Tissue International, 1976